Abstract
ObjectiveMany cancer patients complain about cognitive dysfunction. While cognitive deficits have been attributed to the side effects of chemotherapy, there is evidence for impairment at disease onset, prior to cancer-directed therapy. Further debated issues concern the relationship between self-reported complaints and objective test performance and the role of psychological distress.MethodWe assessed performance on neuropsychological tests of attention and memory and obtained estimates of subjective distress and quality of life in 27 breast cancer patients and 20 healthy controls. Testing in patients took place shortly after the initial diagnosis, but prior to subsequent therapy.ResultsWhile patients showed elevated distress, cognitive performance differed on a few subtests only. Patients showed slower processing speed and poorer verbal memory than controls. Objective and self-reported cognitive function were unrelated, and psychological distress correlated more strongly with subjective complaints than with neuropsychological test performance.ConclusionThis study provides further evidence of limited cognitive deficits in cancer patients prior to the onset of adjuvant therapy. Self-reported cognitive deficits seem more closely related to psychological distress than to objective test performance.
Highlights
Cancer survivors may experience cognitive decline characterized by impaired attention, processing speed, memory or executive functions (Wefel et al, 2004; Bender et al, 2006; Vardy et al, 2007; Dietrich et al, 2008; Lindner et al, 2014; Van Arsdale et al, 2016; Rick et al, 2018)
While there are contradictory findings concerning the associations between subjective and objective cognitive impairments, subjective complaints tended to be more strongly correlated with distress than with performance on neuropsychological tests. These results have given rise to the suggestion that psychological distress caused by the diagnosis of cancer may account for some of the effects previously attributed to chemotherapy. To contribute to this debate, the present study investigated attention and memory in newly diagnosed breast cancer patients and a healthy control group
We focused our investigation on breast cancer because cognitive impairment is of particular relevance to this group of patients due to their high survival rates
Summary
Cancer survivors may experience cognitive decline characterized by impaired attention, processing speed, memory or executive functions (Wefel et al, 2004; Bender et al, 2006; Vardy et al, 2007; Dietrich et al, 2008; Lindner et al, 2014; Van Arsdale et al, 2016; Rick et al, 2018). Several studies have reported cognitive impairment before chemotherapy administration in a certain proportion of breast cancer patients (Hermelink et al, 2007). Several other studies found little or no overall cognitive impairment in cancer patients prior to systemic therapy (Jenkins et al, 2006; Schagen et al, 2006; Debess et al, 2010; Mandelblatt et al, 2014; Hermelink et al, 2015)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
